Leerink Partnrs Has Negative Outlook of Merus Q2 Earnings

Merus (NASDAQ:MRUS - Free Report) - Leerink Partnrs lowered their Q2 2025 earnings estimates for Merus in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings per share of ($1.29) for the quarter, down from their prior forecast of ($1.27). The consensus estimate for Merus' current full-year earnings is ($3.85) per share. Leerink Partnrs also issued estimates for Merus' Q3 2025 earnings at ($1.32) EPS, Q4 2025 earnings at ($1.33) EPS, FY2025 earnings at ($5.33) EPS, FY2026 earnings at ($2.72) EPS and FY2027 earnings at $4.01 EPS.

Other equities research analysts have also issued research reports about the company. Needham & Company LLC reissued a "buy" rating and set a $83.00 price target on shares of Merus in a research note on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Merus in a report on Monday, April 28th. Piper Sandler initiated coverage on Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 price target for the company. Finally, Guggenheim reiterated a "buy" rating and set a $109.00 price objective on shares of Merus in a research report on Friday, March 28th. One research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $85.15.

Merus Stock Performance

MRUS traded down $0.52 on Monday, hitting $40.40. 655,348 shares of the company were exchanged, compared to its average volume of 717,961. The business's fifty day moving average is $43.43 and its 200 day moving average is $43.96. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $61.61. The firm has a market capitalization of $2.80 billion, a P/E ratio of -10.23 and a beta of 0.94.

Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million.

Institutional Investors Weigh In On Merus

A number of institutional investors have recently bought and sold shares of MRUS. Wells Fargo & Company MN lifted its position in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after buying an additional 300 shares in the last quarter. GF Fund Management CO. LTD. lifted its position in Merus by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company's stock valued at $74,000 after buying an additional 315 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in Merus by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company's stock valued at $1,921,000 after buying an additional 331 shares in the last quarter. Knights of Columbus Asset Advisors LLC lifted its position in Merus by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 13,785 shares of the biotechnology company's stock valued at $580,000 after buying an additional 361 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Merus by 0.4% during the fourth quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock valued at $4,754,000 after buying an additional 416 shares in the last quarter. 96.14% of the stock is currently owned by hedge funds and other institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.